OptiBiotix Healthplc(AIM: OPTI),alifesciencesbusinessdevelopingproducts totackleobesity,high cholesterolanddiabetes, announces that Stephen O'Hara, CEO of Optibiotix,will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI") on Monday, 13 May 2019. The event will be held in the City of London and will commence at 5pm.
To register your interest and obtain further details, please contact TPI on[email protected]or call 0203 621 4124.
No new material or trading information will be provided.
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Steve Prescott, CEO of OptiBiotix Health PLC's (LON:OPTI) ProBiotix Health division, speaks to Proactive London while in Europe to meet with some of their key customers and suppliers.
Prescott updates on discussions he's having with a major European probiotic company about a new product as...